内部抗癌疗法耐药性和转移. 把注意力集中在CD3636上
Ioana M Lambrescu1,2, Gisela F Gaina1,2, Laura C Ceafalan1,2
1Cell Biology, Neurosciences, and Experimental Myology Laboratory, Victor Babeș Institute of Pathology, 050096 Bucharest, Romania.
CD36是一种脂质受体,与癌症药物耐药性有关. 针对CD36提供了克服各种癌症治疗耐药性的新策略,为个性化医疗铺平了道路.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 耐药性是癌症治疗的一个主要挑战.
- 脂质代谢在癌症的进展和转移中起着至关重要的作用.
- CD36是一种脂质载体,与各种癌症的不良预后有关.
研究的目的:
- 审查CD36在抗癌疗法的作用.
- 探索CD36在固体和血液性恶性瘤中的参与.
- 总结针对个性化医学的新兴抗CD36疗法.
主要方法:
- 对CD36和癌症药物耐药性研究的文献综述.
- 分析CD36在对基和辅助疗法的耐药性方面的作用.
- 目前和正在发展的抗CD36治疗策略的概述.
主要成果:
- CD36表达与对各种癌症治疗的耐药性有关.
- CD36有助于固体瘤和血液癌症中的耐药性.
- 针对CD36的新兴疗法显示出克服治疗耐药性的前景.
结论:
- CD36是癌症治疗耐药性的关键因素.
- 向CD36为新型癌症疗法提供了一个有希望的途径.
- 对抗CD36策略的进一步研究可能会导致个性化癌症医学.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
12:14CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
Published on: June 2, 2022
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Mitogens and the Cell Cycle
